National Kidney Foundation Honors CareDx with Corporate Citizenship Award for its Commitment to the Transplant Community

CareDx Receives Award for Introducing RemoTraC During Pandemic and Sponsoring the Honor the Gift Coalition for Successful Passage of the Immuno Bill BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that … [Read more…]

Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis

Top-Line Results from Part 1 of the Trial Expected in the Second Half of 2023 LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced enrollment of the first patient in the Phase 2 clinical trial of orally administered RASP modulator ADX‑629, an investigational new drug, for the treatment of atopic dermatitis. The multicenter, adaptive, … [Read more…]

Evopoint Announces Clinical Trial Collaboration Agreement with MSD for the Study of XNW5004 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors

SUZHOU, China–(BUSINESS WIRE)–Evopoint Biosciences Co., Ltd.(“Evopoint”), a biopharmaceutical company focused on discovering and developing innovative and transformative medicines, announced today a collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate Evopoint’s XNW5004, a selective EZH2 inhibitor, in combination with KEYTRUDA®(pembrolizumab), MSD’s anti-PD-1 therapy, in a Phase Ib/II study in Chinese patients with … [Read more…]

Sonendo Announces New Leadership in Operations and R&D

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced changes to its leadership team. Andrew Kirkpatrick, chief operating officer, is stepping down from the position of Chief Operating Officer, effective June 1, 2023, to pursue new opportunities. The Company has also created two new … [Read more…]

Electromedical Products International Forms Scientific Advisory Board

MINERAL WELLS, Texas–(BUSINESS WIRE)–#behavioralhealth–Electromedical Products International, Inc. (EPI), manufacturer of Alpha-Stim® technology, announced today the formation of its Scientific Advisory Board (SAB) comprising leading clinicians and researchers in neurology, psychiatry and neurostimulation. The SAB will work closely with EPI’s leadership team to provide scientific and clinical input into the company’s clinical trials in non-invasive brain … [Read more…]

Fortune Media and Great Place To Work® Name Vizient to 2023 Fortune 100 Best Companies to Work For®, Ranking No. 45

IRVING, Texas–(BUSINESS WIRE)–Great Place To Work® and Fortune magazine have honored Vizient, Inc. as one of the 2023 Fortune 100 Best Companies to Work For®. This is Vizient’s second time being named to this prestigious list, this year coming in at No. 45. Earning a spot means that Vizient has surpassed rigorous benchmarks, establishing itself … [Read more…]

ADM and Brightseed Launch Global Partnership To Decode How The Gut Microbiome & Bioactives Impact Human Health

ADM invests in Brightseed to identify bioactives from microbe and plant interactions to develop the future of clinically validated synbiotic products CHICAGO & SAN FRANCISCO–(BUSINESS WIRE)–ADM, a global leader in nutrition that powers many of the world’s top food, beverage, and health and wellness brands, and Brightseed, the bioactives company and a World Economic Forum … [Read more…]

Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study

Memorial Sloan Kettering Cancer Center and Fred Hutch Cancer Center now open for patient enrolment to pre|CISION™ lead programme, AVA6000 LONDON & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces the opening on 5 April 2023 of the first two clinical investigator sites … [Read more…]

Dexcom Schedules First Quarter 2023 Earnings Release and Conference Call for April 27, 2023 at 4:30 p.m. Eastern Time

SAN DIEGO–(BUSINESS WIRE)–DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2023 financial results after market close on Thursday, April 27, 2023. Management will hold a conference call to review the company’s first quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be … [Read more…]

Global Fetal Monitoring, Diagnostics and Predictive Tests Report 2023: Sector to Reach $13.6 Billion by 2027 at a CAGR of 5.6% – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Fetal Monitoring, Diagnostics and Predictive Tests” report has been added to ResearchAndMarkets.com’s offering. The global fetal monitoring, diagnostics and predictive tests market is expected to reach $13.6 billion by 2027 from $10.4 billion in 2022 at a CAGR of 5.6% This report aims to provide a comprehensive study of the global market for … [Read more…]